Eevia is subject to a possible reverse takeover
Eevia Health Plc (”Eevia" or "The Company") received a proposal for a reverse takeover (RTO) from Stemtech Corporation[1] (“Stemtech”), a US company, on November 10. The proposal suggests that Eevia buy the US company's assets (“Stemtech Assets”) and issue new shares to the US company, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech recently announced its pending merger with Seacret Direct LLC, DBA VIÁGO ("Viago"), and the Stemtech Assets include the assets of Viago and Stemtech. Stemtech's valuation would be approximately 40 MUSD,